Anti-Human CD3 mAb, mouse IgG1 (Clone # SP34-2) immobilized on CM5 Chip can bind Human CD3 epsilon, Mouse IgG2a Fc Tag (Cat. No. CDN-H5253) with an affinity constant of 75.2 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Monoclonal Anti-Human CD3 Antibody, Mouse IgG1 (SP34-2) (Cat. No. CDE-M531) captured on CM5 chip via anti-mouse antibodies surface can bind Human CD3 epsilon, His Tag (Cat. No. CDE-H5223) with an affinity constant of 0.394 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Elranatamab | RN-613; PF-06863135; PF‑3135 | Approved | Pfizer Inc | Elrexfio, ELREXFIO, ELREXFIO™ | United States | Multiple Myeloma | Pfizer Inc | 2023-08-14 | Bone Marrow Neoplasms; Smoldering Multiple Myeloma; Multiple Myeloma | Details |
Glofitamab | RG-6026; RO-7082859; RG6026-2 | Approved | F. Hoffmann-La Roche Ltd | COLUMVI, 高罗华 | Canada | Lymphoma, Large B-Cell, Diffuse | F. Hoffmann-La Roche Ltd | 2023-03-25 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma | Details |
Talquetamab | JNJ-7564; JNJ-64407564 | Approved | Johnson & Johnson Innovative Medicine, Genmab A/S | TALVEY | United States | Multiple Myeloma | Janssen Biotech Inc | 2023-08-09 | Hematologic Neoplasms; Multiple Myeloma | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Obrindatamab | MGD-009; B7-H3 x CD3 | Phase 2 Clinical | Macrogenics Inc | Mesothelioma; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Neoplasms; Sarcoma; Neuroblastoma; Neurofibrosarcoma; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Sarcoma, Synovial; Urinary Bladder Neoplasms; Wilms Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma | Details |
Emerfetamab | AMG-673; AMG673 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
Pacanalotamab | AMG-420; BI-836909 | Phase 1 Clinical | Micromet Inc | Multiple Myeloma | Details |
Gresonitamab | AMG-910 | Phase 1 Clinical | Amgen Inc | Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma | Details |
Eluvixtamab | MT-114; AMG-330 | Phase 1 Clinical | Amgen Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Etevritamab | AMG-596 | Phase 1 Clinical | Amgen Inc | Glioblastoma | Details |
This web search service is supported by Google Inc.